文献速递白血病淋巴瘤

体外药物反应分析可检测耐药急性淋巴细胞白血病中反复出现的敏感性模式

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2017-01-25

研究对68例急性淋巴细胞白血病(ALL)样本(多来自耐药疾病)在骨髓基质细胞共培养中检测60种药物的敏感性,发现基质共培养不阻止白血病细胞周期活性,细胞周期相关药物的敏感性模式可识别体内外高增殖样本;1例难治性T-ALL根据药物分析信息使用达沙替尼获得5个月缓解。

要点

  • 在骨髓基质共培养中对68例ALL样本检测60种药物,可检出反复出现的药物敏感性模式。
  • BCP-ALL亚群(含MLL-AF4和TCF3-HLF ALL)及部分T-ALL对venetoclax在10 nM以下高度敏感。
  • 2个独立T-ALL队列中检测到对达沙替尼的意外敏感性,半数抑制浓度低于20 nM。

核心结论

  • 药物分析可捕获疾病相关特征及对相关药物的意外敏感性,值得在临床试验背景下进一步探索该功能检测,以期为有紧急医疗需求的患者制定药物再利用策略。

研究设计与样本

  • 研究对68例急性淋巴细胞白血病(ALL)样本(多来自耐药疾病)在骨髓基质细胞共培养中检测60种药物的敏感性,并比较患者来源异种移植瘤与原患者材料的突变模式。

主要发现

  • 基质共培养未阻止白血病细胞周期活性,但细胞周期相关药物的特定敏感性模式可识别体外和体内作为白血病异种移植瘤时细胞增殖更高的样本。
  • 在难治性复发病例中检测到个体化的显著耐药模式及对具有即时临床相关性的新药的异常反应。
  • BCL2抑制剂venetoclax在10 nM以下对B细胞前体ALL(BCP-ALL)亚群(包括MLL-AF4和TCF3-HLF ALL)及部分T细胞ALL(T-ALL)高度活跃,预测了其作为单药以及与地塞米松和长春新碱联合的体内活性。
  • 在2个独立T-ALL队列中检测到对达沙替尼的意外敏感性,半数抑制浓度值低于20 nM,与SRC抑制剂KX2-391的类似细胞毒活性及SRC磷酸化抑制相关。
  • 1例难治性T-ALL患者根据药物分析信息接受达沙替尼治疗,获得5个月缓解。

临床怎么用

  • 1例难治性T-ALL患者基于药物分析信息接受达沙替尼治疗并获得5个月缓解,作者认为该功能检测值得在临床试验背景下进一步探索以制定药物再利用策略。

局限性

  • 原文在结论中提出该功能检测值得在临床试验背景下进一步探索,表明其临床价值尚需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery. We provide proof of concept data by profiling 60 drugs on 68 acute lymphoblastic leukemia (ALL) samples mostly from resistant disease in cocultures of bone marrow stromal cells. Patient-derived xenografts retained the original pattern of mutations found in the matched patient material. Stromal coculture did not prevent leukemia cell cycle activity, but a specific sensitivity profile to cell cycle-related drugs identified samples with higher cell proliferation both in vitro and in vivo as leukemia xenografts. In patients with refractory relapses, individual patterns of marked drug resistance and exceptional responses to new agents of immediate clinical relevance were detected. The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Unexpected sensitivity to dasatinib with half maximal inhibitory concentration values below 20 nM was detected in 2 independent T-ALL cohorts, which correlated with similar cytotoxic activity of the SRC inhibitor KX2-391 and inhibition of SRC phosphorylation. A patient with refractory T-ALL was treated with dasatinib on the basis of drug profiling information and achieved a 5-month remission. Thus, drug profiling captures disease-relevant features and unexpected sensitivity to relevant drugs, which warrants further exploration of this functional assay in the context of clinical trials to develop drug repurposing strategies for patients with urgent medical needs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Frismantas V, Dobay MP, Rinaldi A, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017. PMID: 28122742. doi:10.1182/blood-2016-09-738070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。